DE60011761D1 - Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen - Google Patents
Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellenInfo
- Publication number
- DE60011761D1 DE60011761D1 DE60011761T DE60011761T DE60011761D1 DE 60011761 D1 DE60011761 D1 DE 60011761D1 DE 60011761 T DE60011761 T DE 60011761T DE 60011761 T DE60011761 T DE 60011761T DE 60011761 D1 DE60011761 D1 DE 60011761D1
- Authority
- DE
- Germany
- Prior art keywords
- arpe
- cell line
- cells
- administrating
- platform cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12792699P | 1999-04-06 | 1999-04-06 | |
US127926P | 1999-04-06 | ||
US543119 | 2000-04-05 | ||
US09/543,119 US6361771B1 (en) | 1999-04-06 | 2000-04-05 | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
PCT/US2000/009150 WO2000060051A2 (en) | 1999-04-06 | 2000-04-06 | Arpe-19 as a platform cell line for encapsulated cell-based delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60011761D1 true DE60011761D1 (de) | 2004-07-29 |
DE60011761T2 DE60011761T2 (de) | 2005-08-04 |
Family
ID=26826092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60011761T Expired - Lifetime DE60011761T2 (de) | 1999-04-06 | 2000-04-06 | Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen |
Country Status (12)
Country | Link |
---|---|
US (2) | US6361771B1 (de) |
EP (1) | EP1171573B1 (de) |
JP (2) | JP4954374B2 (de) |
AT (1) | ATE269715T1 (de) |
AU (1) | AU773387B2 (de) |
BR (1) | BR0009562A (de) |
CA (1) | CA2365532C (de) |
DE (1) | DE60011761T2 (de) |
DK (1) | DK1171573T3 (de) |
ES (1) | ES2219335T3 (de) |
NO (1) | NO20014856D0 (de) |
WO (1) | WO2000060051A2 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878544B2 (en) * | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
US20070071734A1 (en) * | 1999-04-06 | 2007-03-29 | Weng Tao | ARPE-19 as platform cell line for encapsulated cell-based delivery |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
WO2003033016A1 (en) * | 2001-10-16 | 2003-04-24 | Jenny Phipps | Use of neurotrophic factors for treating neurodegenerative diseases and cancer |
AU2003221579A1 (en) * | 2002-04-30 | 2003-11-17 | Canadian Blood Services | Encapsulated cells to elicit immune response |
JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | 潤滑油組成物 |
ATE433759T1 (de) | 2003-04-18 | 2009-07-15 | Biogen Idec Inc | Polymerkonjugiertes glycosiliertes neublastin |
ATE423134T1 (de) * | 2003-06-10 | 2009-03-15 | Nsgene As | Verbesserte sezernierung von neublastin |
US7927599B2 (en) * | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US8257963B2 (en) * | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US7598059B2 (en) * | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
DE602004025959D1 (de) | 2003-10-20 | 2010-04-22 | Nsgene As | Viraler Vektor zur Verwendung in der in-vivo-Gentherapie von Morbus Parkinson |
CN1897977A (zh) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
EP2289911A3 (de) | 2004-03-30 | 2011-03-30 | NsGene A/S | Therapeutische Verwendung des Wachstumsfaktors nsg33 |
CA2577755C (en) * | 2004-08-19 | 2014-05-13 | Biogen Idec Ma Inc. | Neublastin variants |
JP4959566B2 (ja) * | 2004-08-19 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | トランスホーミング増殖因子βファミリータンパク質の折りたたみ |
AU2006228873B2 (en) * | 2005-04-01 | 2011-08-18 | Nsgene A/S | A human immortalised neural precursor cell line |
EP1883446B8 (de) * | 2005-05-17 | 2017-11-15 | Gloria Therapeutics Sarl | Implantierbares therapiesystem zur behandlung eines lebewesens mit einem wirkfaktor |
WO2007042040A2 (en) * | 2005-10-11 | 2007-04-19 | Ns Gene A/S | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS |
WO2007048413A1 (en) * | 2005-10-28 | 2007-05-03 | Nsgene A/S | IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF |
JP5247468B2 (ja) * | 2005-12-30 | 2013-07-24 | ニューロテック ユーエスエー, インコーポレイテッド | 生物活性分子の送達のための微粒子化デバイスおよびその使用方法 |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
US20100056440A1 (en) * | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
US8329655B2 (en) * | 2007-05-01 | 2012-12-11 | Biogen Idec Ma Inc. | Methods for increasing vascularization |
EP2205634A2 (de) * | 2007-08-08 | 2010-07-14 | Biogen Idec MA, Inc. | Anti-neublastin-antikörper und anwendungen davon |
US20090196854A1 (en) * | 2008-02-04 | 2009-08-06 | Kytos Biosystems S.A. | Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
US8075537B2 (en) * | 2008-08-15 | 2011-12-13 | Oxyband Technologies, Inc. | Multiple cell therapeutic diffusion device |
JP5897335B2 (ja) | 2009-01-23 | 2016-03-30 | エヌエスジーン・アクティーゼルスカブNsGene A/S | 改良された細胞株及びカプセル化細胞生体送達におけるその使用 |
US20120021039A1 (en) | 2009-01-23 | 2012-01-26 | Nsgene A/S | Expression of neuropeptides in mammalian cells |
US20150024024A1 (en) * | 2009-04-23 | 2015-01-22 | Neurotech Usa, Inc. | Cell Lines That Produce Prostaglandin F2 Alpha (PGF2A) And Uses Thereof |
CA2776748A1 (en) * | 2009-10-08 | 2011-04-14 | Neurotech Usa, Inc. | Use of pedf in an encapsulated cell-based delivery system |
US20110104154A1 (en) * | 2009-10-30 | 2011-05-05 | Alcon Research, Ltd. | Single nucleotide polymorphisms and genes associated with age-related macular degeneration |
WO2012009377A2 (en) | 2010-07-12 | 2012-01-19 | University Of Southern California | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
CN103269708A (zh) | 2010-10-01 | 2013-08-28 | Ns基因公司 | 镍纹蛋白用于治疗异常性疼痛、痛觉过敏、自发性疼痛和幻痛的用途 |
US9149427B2 (en) | 2010-12-02 | 2015-10-06 | Neurotech Usa, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
US10478206B2 (en) | 2011-04-29 | 2019-11-19 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
CN104321069A (zh) | 2011-10-27 | 2015-01-28 | 威尔斯达眼科制剂公司 | 编码视杆细胞来源的视锥细胞活力因子的载体 |
US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
JP2015519370A (ja) | 2012-05-30 | 2015-07-09 | ニューロテック ユーエスエー, インコーポレイテッド | 低温保存される植込み型細胞培養デバイスおよびその使用 |
WO2014200997A2 (en) * | 2013-06-10 | 2014-12-18 | Millennium Pharmaceuticals, Inc. | Method for preparing three-dimensional, organotypic cell cultures and uses thereof |
AU2014318846A1 (en) | 2013-09-11 | 2016-03-10 | Neurotech Usa, Inc. | Encapsulated cell therapy cartridge |
FR3014316B1 (fr) * | 2013-12-10 | 2017-01-20 | Defymed | Organe bioartificiel |
WO2016036322A1 (en) | 2014-09-04 | 2016-03-10 | Kemijski inštitut | Cell-based device for local treatment with therapeutic protein |
ES2833457T3 (es) * | 2015-05-27 | 2021-06-15 | Neurotech Usa Inc | Uso de terapia con células encapsuladas para el tratamiento del glaucoma |
KR20220151598A (ko) | 2019-11-01 | 2022-11-15 | 뉴로테크 유에스에이, 인코포레이티드. | 피분석물 확산 이식 가능 디바이스를 패키징하기 위한 시스템, 장치, 디바이스 및 방법 |
WO2021204935A1 (en) | 2020-04-09 | 2021-10-14 | Defymed | Membranes for medical devices |
EP3892259A1 (de) | 2020-04-09 | 2021-10-13 | Defymed | Membranen für medizinische vorrichtungen |
WO2022011081A1 (en) | 2020-07-09 | 2022-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cell lines that produce human retinoschisin proteins and uses thereof |
KR20240006581A (ko) | 2021-05-06 | 2024-01-15 | 호바 세라퓨틱스 에이피에스 | 화학요법-유도된 신경병성 통증의 예방 및 치료 |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
EP0585368B1 (de) | 1991-04-25 | 1997-08-06 | Brown University Research Foundation | Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
FR2681609B1 (fr) | 1991-09-24 | 1994-12-30 | Centre Nat Rech Scient | Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale. |
EP0653943A4 (de) | 1992-07-13 | 1996-10-02 | Baylor College Medicine | Eine somatische gentherapie auf gelenke zielend. |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
NZ269041A (en) | 1993-06-23 | 1998-02-26 | Univ Brown Res Found | Implantable encapsulation device having a cell-tight dry seal at an opening thereof |
CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
US6020192A (en) * | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
US5998598A (en) * | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
-
2000
- 2000-04-05 US US09/543,119 patent/US6361771B1/en not_active Expired - Lifetime
- 2000-04-06 AU AU43319/00A patent/AU773387B2/en not_active Expired
- 2000-04-06 EP EP00923144A patent/EP1171573B1/de not_active Expired - Lifetime
- 2000-04-06 CA CA2365532A patent/CA2365532C/en not_active Expired - Lifetime
- 2000-04-06 DK DK00923144T patent/DK1171573T3/da active
- 2000-04-06 WO PCT/US2000/009150 patent/WO2000060051A2/en active IP Right Grant
- 2000-04-06 DE DE60011761T patent/DE60011761T2/de not_active Expired - Lifetime
- 2000-04-06 AT AT00923144T patent/ATE269715T1/de active
- 2000-04-06 ES ES00923144T patent/ES2219335T3/es not_active Expired - Lifetime
- 2000-04-06 US US09/958,040 patent/US7115257B1/en not_active Expired - Lifetime
- 2000-04-06 BR BRPI0009562-1A patent/BR0009562A/pt not_active IP Right Cessation
- 2000-04-06 JP JP2000609543A patent/JP4954374B2/ja not_active Expired - Lifetime
-
2001
- 2001-10-05 NO NO20014856A patent/NO20014856D0/no not_active Application Discontinuation
-
2010
- 2010-11-16 JP JP2010256357A patent/JP2011074079A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2000060051A8 (en) | 2001-04-05 |
WO2000060051A2 (en) | 2000-10-12 |
AU4331900A (en) | 2000-10-23 |
DE60011761T2 (de) | 2005-08-04 |
JP4954374B2 (ja) | 2012-06-13 |
EP1171573A1 (de) | 2002-01-16 |
WO2000060051A3 (en) | 2002-03-28 |
CA2365532A1 (en) | 2000-10-12 |
JP2003524621A (ja) | 2003-08-19 |
US7115257B1 (en) | 2006-10-03 |
CA2365532C (en) | 2012-11-06 |
JP2011074079A (ja) | 2011-04-14 |
EP1171573B1 (de) | 2004-06-23 |
NO20014856D0 (no) | 2001-10-05 |
AU773387B2 (en) | 2004-05-27 |
ATE269715T1 (de) | 2004-07-15 |
DK1171573T3 (da) | 2004-09-27 |
ES2219335T3 (es) | 2004-12-01 |
US6361771B1 (en) | 2002-03-26 |
BR0009562A (pt) | 2007-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60011761D1 (de) | Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen | |
Jiang et al. | Local release of dexamethasone from macroporous scaffolds accelerates islet transplant engraftment by promotion of anti-inflammatory M2 macrophages | |
Rocchi et al. | Mouth-watering results: Clinical need, current approaches, and future directions for salivary gland regeneration | |
Chae et al. | Protection of insulin secreting cells from nitric oxide induced cellular damage by crosslinked hemoglobin | |
Wong et al. | Pullulan hydrogels improve mesenchymal stem cell delivery into high‐oxidative‐stress wounds | |
CN101919380B (zh) | 一种改进的间充质干细胞保护液及其用途 | |
Duvivier-Kali et al. | Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane | |
Kokoshis et al. | Increased resistance to Staphylococcus aureus infection and enhancement in serum lysozyme activity by glucan | |
Carrade et al. | Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions | |
FI873084A (fi) | Uudet immobilisoidut biokatalysaattorit sekä niiden valmistus ja käyttö | |
Liao et al. | Maintaining functional islets through encapsulation in an injectable saccharide–peptide hydrogel | |
EP1553893A2 (de) | Implantation von verkapseltem biologischem material zur behandlung von krankheiten | |
ATE284674T1 (de) | Hybride matrizen und gemische davon | |
Delmastro-Greenwood et al. | Effects of metalloporphyrins on reducing inflammation and autoimmunity | |
CN101466360A (zh) | 用于细胞移植的多膜免疫隔离系统 | |
Leung et al. | Microencapsulation of crystalline insulin or islets of Langerhans: an insulin diffusion study | |
Matsushima et al. | Bidirectional homing of Tregs between the skin and lymph nodes | |
WO2017024076A1 (en) | Cell transplantation device | |
Shin et al. | Recyclable cytokines on short and injectable polylactic acid fibers for enhancing T‐cell function | |
Ouaissi et al. | Glutathione S-transferases and related proteins from pathogenic human parasites behave as immunomodulatory factors | |
Slavin et al. | Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation | |
KR20120013358A (ko) | 사람 또는 동물 체표면 감염의 치료 | |
Sakai et al. | Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors | |
WO2020210458A1 (en) | Pulsed focused ultrasound therapy for treatment of pancreatic disorders | |
NO20000990D0 (no) | Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta> |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: NEUROTECH S.A., PARIS, FR |
|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NEUROTECH USA, INC. (N. D. GES. D. STAATES DEL, US |